02616 CSTONE PHARMA-BWatchlist
CSTONE PHARMA-B News
Hong Kong Stock Announces Nuggets | Strategic Cooperation with Foreign Countries: World's First and Only R/R ENKTL Immunotherapy Drug Approved to Open Overseas Markets
Puget is a potent, highly selective inhibitor that accurately targets RET targets.
Cornerstone Pharmaceutical-B (02616.HK): Grants 14 million share options under the post-IPO employee stock ownership plan
On November 9, Gelonghui - Cornerstone Pharmaceutical-B (02616.HK) issued an announcement. On November 8, 2023, the company granted Dr. Yang Jianxin a total of 14 million share options to subscribe for a total of 14 million shares in accordance with the initial public offering after-sales employee stock ownership plan.
Cornerstone Pharmaceutical (02616) continues strategic cooperation with foreign countries and joins hands with Alice (688578.SH) to jointly develop the Chinese market in Phuket
On November 8, Hong Kong-stock innovative pharmaceutical company Cornerstone Pharmaceutical (02616) announced that it will grant the exclusive commercialization rights for Pujihua (platinib capsules), the first RET inhibitor in China in mainland China, to Alice Pharmaceuticals (688578.SH), a company listed on the Science and Technology Innovation Board.
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China
3SBio (HKG:1530) struck an exclusive licensing agreement to develop, manufacture and commercialize CStone Pharmaceuticals' (HKG:2616) anti-tumor medication nofazinlimab (CS1003) in mainland China. The
Cornerstone Pharmaceutical-B (02616.HK): A new indication of suglizumab for recurrent or refractory extranodal NK/T-cell lymphoma was approved in China, becoming the first PD-1 or PD-L1 monoclonal antibody approved for this indication
On October 31, Gelonghui - Cornerstone Pharmaceutical-B (02616.HK) issued an announcement that China's National Drug Administration (NMPA) has approved the PD-L1 antibody suglimab (zeglizumab) for the treatment of patients with recurrent or refractory extranodal NK/T cell lymphoma (R/R ENKTL). As a result, suglimab became the world's first tumor immunotherapy drug approved for R/R ENKTL indications. Dr. Yang Jianxin, CEO and Executive Director of Cornerstone Pharmaceutical, said, “We are very pleased that suglimab has been recognized by the NMPA again. R/R ENKTL indications
CStone Pharmaceutical Awaits Chinese Approval for Anti-Cancer Drug
CStone Pharmaceuticals (HKG:2616) said Chinese regulator NMPA is currently reviewing the supplemental biologics license application (sBLA) for the firm's sugemalimab drug, in combination with chemotherapy, as a first-line treatment for gastroesophageal cancer.
[Hong Kong Stock Connect] Cornerstone Pharmaceutical-B (02616) announces registered clinical study data on first-line treatment of gastroesophageal joint adenocarcinoma with sugarlizumab
Jinwu Financial News | Cornerstone Pharmaceutical-B (02616) announced that GEMSTONE-303, a phase III study of sugarlizumab (Sugarizumab) combined with chemotherapy to treat locally advanced or metastatic gastroesophageal junction adenocarcinoma, has been selected for the 2023 European Society of Internal Oncology (ESMO) Annual Meeting Summary (LBA) (late-breaking abstract, LBA), and published detailed data in the form of an oral report. GEMSTONE-303 study results showed that suglizumab combined with chemotherapy, as first-line treatment, can significantly prolong locally advanced or metastatic stomach/
Cornerstone Pharmaceutical (02616) Announces GEMSTONE-303 Study Results: Ze Jie Mei Combined with Chemotherapy Significantly Improved PFS and OS
Cornerstone Pharmaceutical (02616) announced registered clinical study data on frontline treatment of gastroesophageal adenocarcinoma with Zeglimab (suglizumab injection) at the 2023 ESMO Annual Meeting in the form of an oral report.
Private Equity Firms Among CStone Pharmaceuticals' (HKG:2616) Largest Stockholders and Were Hit After Last Week's 16% Price Drop
Key Insights Significant control over CStone Pharmaceuticals by private equity firms implies that the general public has more power to influence management and governance-related decisions The top 5
CStone CEO to Boost Share Count; Shares Fall 9%
CStone Pharmaceuticals (HKG:2616) Chief Executive Officer Jianxin Yang plans to purchase additional shares in the open market for about HK$5 million, according to a Tuesday filing. Yang has so far bou
Cornerstone Pharmaceutical-B (02616.HK): CEO and Executive Director Yang Jianxin plans to increase the total amount of shares not expected to exceed HK$5 million
Glonghui, October 3: Cornerstone Pharmaceutical-B (02616.HK) issued an announcement. The board of directors was informed by Dr. Yang Jianxin (CEO and executive director of the company) that while complying with applicable laws and regulations, Dr. Yang intends to acquire the company's shares on the open market within about six months from the date of this announcement. According to information provided by Dr. Yeung, the total cost of additional shareholding is expected to be no more than HK$5 million. Furthermore, according to Dr. Yang, the shares to be increased will be used for medium- to long-term investment purposes, and there is currently no intention to sell the relevant shares within 12 months after the increase in shares. The capital required to increase shareholding is owned by oneself or by oneself
Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) has now risen by more than 4%, the results of the first human trial of the PD-1 antibody nofazinlimab have been announced
Cornerstone Pharmaceutical-B (02616) is now up more than 4%. As of press release, it has risen 4.23% to HK$1.97, with a turnover of HK$3,516,000.
CSTONE PHARMA-B: INTERIM REPORT 2023
Cornerstone Pharmaceutical-B (02616.HK): A registered clinical study on first-line treatment of gastroesophageal junction adenocarcinoma with sugarlizumab reached the main end point of overall survival
Glonghui, August 29丨Cornerstone Pharmaceutical-B (02616.HK) announced that the phase III study (GEMSTONE-303) of locally advanced or metastatic gastroesophageal adenocarcinoma with PD-L1 expression ≥ 5% that cannot be surgically removed during first-line treatment with suglizumab combined with chemotherapy has reached the main end point of overall survival (OS). Compared with the placebo plus chemotherapy control group, sugarizumab combined with chemotherapy can significantly prolong the overall survival time of patients, and the difference is statistically significant and clinically significant. Safety is consistent with previously reported clinical study results related to sugarizumab, and no new ones have been discovered
Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose by more than 5%, and the company's rapid commercialization volume, and many indications are expected to continue to be implemented
Cornerstone Pharmaceutical-B (02616) rose more than 5%. As of press release, it rose 4.5% to HK$2.32, with a turnover of HK$5.994 million.
[Brokerage Focus] Southwest Securities maintains the “buy” rating of the cornerstone pharmaceutical industry (02616) indicates that commercialization is progressing steadily and the pipeline is about to be implemented
According to the Southwest Securities Research Report, Cornerstone Pharmaceutical (02616) announced its 2023 interim results. Total revenue for the first half of 2022 reached 260 million yuan and commercial revenue of 250 million yuan (+53%). The performance was in line with expectations. According to the bank, the CS5001 is an ROR1 ADC. Only three ROR1 ADCs are in the clinical stage in the world. The first two models were acquired by MSD and Boehringer Ingelheim (BI) at high prices of 2.75 billion and 1.43 billion US dollars respectively. The reason for this is that ROR1 is a tumor embryonic protein and is highly expressed in various solid tumors and hematomas, such as non-small cell lung cancer, leukemia, and lymphoma
CStone Pharmaceuticals' H1 Loss Narrows
CStone Pharmaceuticals' (HKG:2616) loss narrowed to 210.1 million yuan, or 0.17 yuan per share, in the first half, from 361.6 million yuan, or 0.31 yuan per share, in the year-ago period, a Tuesday fi
CSTONE PHARMA-B: ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2023
Insider Buyers At CStone Pharmaceuticals Likely Disappointed With 15% Slide
The recent price decline of 15% in CStone Pharmaceuticals' (HKG:2616) stock may have disappointed insiders who bought CN¥14m worth of shares at an average price of CN¥3.45 in the past 12 months. This
CSTONE PHARMA-B: DATE OF BOARD MEETING